Rational Design of Potent Activators and Inhibitors of the Enterococcus Faecalis Fsr Quorum Sensing Circuit
Overview
Biology
Affiliations
The increasing rate of resistance development to conventional antibiotics by bacteria necessitates the identification of alternative treatment possibilities that can reduce the ability of bacteria to adapt. Enterococcus faecalis remains the leading cause of clinical enterococci infections and has exhibited quorum sensing (QS)-dependent pathogenicity. Here, we report the development of macrocyclic peptide-based activators and inhibitors of the E. faecalis Fsr QS circuitry. To this end, we developed, optimized, and compared three synthetic routes for lactone-containing macrocyclic peptide scaffolds. We then utilized previous and current structure-activity relationship (SAR) insights of the native QS signaling peptide to rationally design the most potent activators and inhibitors of the Fsr QS circuitry identified to date. The application of these peptides could provide a means to attenuate the pathogenicity of E. faecalis without introducing significant selective pressure on the bacteria to develop resistance.
Polidocanol inhibits Enterococcus faecalis virulence factors by targeting fsr quorum sensing system.
Ashraf D, Shaaban M, Hassan R, El-Aziz A BMC Microbiol. 2024; 24(1):411.
PMID: 39415105 PMC: 11481293. DOI: 10.1186/s12866-024-03548-2.
Yehuda A, Malach E, Vanunu Ofri S, Slamti L, Kuo S, Lau J Proc Natl Acad Sci U S A. 2023; 120(35):e2301045120.
PMID: 37607229 PMC: 10469338. DOI: 10.1073/pnas.2301045120.
Lyagin I, Stepanov N, Presnov D, Trifonov A, Efremenko E Int J Mol Sci. 2023; 24(3).
PMID: 36768158 PMC: 9915939. DOI: 10.3390/ijms24031831.
McBrayer D, Ghosh U, Lella M, Cameron C, Tal-Gan Y Chembiochem. 2022; 24(1):e202200527.
PMID: 36376247 PMC: 9812899. DOI: 10.1002/cbic.202200527.
Peptidomimetics as Potential Anti-Virulence Drugs Against Resistant Bacterial Pathogens.
Martinez O, Duque H, Franco O Front Microbiol. 2022; 13:831037.
PMID: 35516442 PMC: 9062693. DOI: 10.3389/fmicb.2022.831037.